Literature DB >> 24890719

T cell activation regulates CD6 alternative splicing by transcription dynamics and SRSF1.

Vânia G da Glória1, Mafalda Martins de Araújo2, Ana Mafalda Santos3, Rafaela Leal1, Sérgio F de Almeida4, Alexandre M Carmo5, Alexandra Moreira6.   

Abstract

The T cell-surface glycoprotein CD6 is a modulator of cellular responses and has been implicated in several autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and psoriasis. During Ag presentation, CD6 is targeted to the immunological synapse in a ligand binding-dependent manner, in which CD6 domain 3 directly contacts CD166, expressed on the APC. T cell activation results in the induction of CD6Δd3, an alternatively spliced isoform that lacks the ligand-binding domain and thus no longer localizes at the immunological synapse. In this study, we investigated the molecular mechanisms regulating the expression of CD6Δd3 upon human primary T cell activation. Using chromatin immunoprecipitation, we observed an increase in RNA polymerase II occupancy along the CD6 gene and augmented CD6 transcription. We showed that activation leads to transcription-related chromatin modifications, revealed by higher CD6 acetylation levels. Modulation of chromatin conformation using a histone deacetylase inhibitor that increases transcription rate causes an increase of exon 5 skipping. We further showed that the splicing factor SRSF1 binds to a regulatory element in CD6 intron 4, activating exon 5 splicing and promoting exon 5 inclusion. Concomitant with T cell activation-induced exon 5 skipping, we observed a downregulation of SRSF1. Using RNA immunoprecipitation, we showed that in activated T cells, SRSF1 recruitment to the CD6 transcript is impaired by increased chromatin acetylation levels. We propose that upon T cell activation, SRSF1 becomes limiting, and its function in CD6 exon 5 splicing is countered by an increase in CD6 transcription, dependent on chromatin acetylation.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24890719     DOI: 10.4049/jimmunol.1400038

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  More than a messenger: Alternative splicing as a therapeutic target.

Authors:  A J Black; J R Gamarra; J Giudice
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-02       Impact factor: 4.490

2.  The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.

Authors:  P C Rodríguez; D M Prada; E Moreno; L E Aira; C Molinero; A M López; J A Gómez; I M Hernández; J P Martínez; Y Reyes; J M Milera; M V Hernández; R Torres; Y Avila; Y Barrese; C Viada; E Montero; P Hernández
Journal:  Clin Exp Immunol       Date:  2017-11-16       Impact factor: 4.330

Review 3.  The RNA binding protein SRSF1 is a master switch of gene expression and regulation in the immune system.

Authors:  Sean Paz; Anastasia Ritchie; Christopher Mauer; Massimo Caputi
Journal:  Cytokine Growth Factor Rev       Date:  2020-11-02       Impact factor: 7.638

Review 4.  Post-transcriptional control of T-cell cytokine production: Implications for cancer therapy.

Authors:  Julian J Freen-van Heeren
Journal:  Immunology       Date:  2021-05-10       Impact factor: 7.215

5.  Genetic polymorphisms of cell adhesion molecules in Behcet's disease in a Chinese Han population.

Authors:  Minming Zheng; Lijun Zhang; Hongsong Yu; Jiayue Hu; Qingfeng Cao; Guo Huang; Yang Huang; Gangxiang Yuan; Aize Kijlstra; Peizeng Yang
Journal:  Sci Rep       Date:  2016-04-25       Impact factor: 4.379

Review 6.  CD6, a Rheostat-Type Signalosome That Tunes T Cell Activation.

Authors:  Carine M Gonçalves; Sónia N Henriques; Rita F Santos; Alexandre M Carmo
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

7.  Domain-specific CD6 monoclonal antibodies identify CD6 isoforms generated by alternative-splicing.

Authors:  Rita F Santos; Liliana Oliveira; Marion H Brown; Alexandre M Carmo
Journal:  Immunology       Date:  2019-06-23       Impact factor: 7.397

8.  Alternative Splicing of Toll-Like Receptor 9 Transcript in Teleost Fish Grouper Is Regulated by NF-κB Signaling via Phosphorylation of the C-Terminal Domain of the RPB1 Subunit of RNA Polymerase II.

Authors:  Frank Fang-Yao Lee; Cho-Fat Hui; Tien-Hsien Chang; Pinwen Peter Chiou
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

9.  T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.

Authors:  Usha Bughani; Arindam Saha; Anshu Kuriakose; Reshmi Nair; Ravindra B Sadashivarao; Rasika Venkataraman; Swati Patel; Anuja Tushar Deshchougule; Satish Kumar S; Enrique Montero; Harish V Pai; Dinesh V Palanivelu; Ramakrishnan Melarkode; Pradip Nair
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

10.  Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells.

Authors:  Marjolein B M Meddens; Svenja F B Mennens; F Burcu Celikkol; Joost Te Riet; Johannes S Kanger; Ben Joosten; J Joris Witsenburg; Roland Brock; Carl G Figdor; Alessandra Cambi
Journal:  Front Immunol       Date:  2018-10-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.